A4C Formal Comments on Controlled Substances Forecasting

On August 27, 2025, Angels for Change was featured at the Reagan-Udall Foundation for the FDA’s Public Meeting on Demand Forecasting for Controlled Substances in Washington, DC. Our founder, Laura Bray, was a featured panelist.

In our public comments for the record, we highlighted how outdated and inflexible forecasting processes are leaving patients without access to critical medicines. We called for a more transparent, patient-centered approach that:

• Anchors demand forecasting in real-world patient care rather than sales data

• Brings together stakeholders across the supply chain, prescribers, and patient advocates

• Builds regulatory flexibility to respond to changing patient needs

“We must anchor forecasting in patient care, reimbursement realities, and supply chain insight — not in sales numbers skewed by a constrained, quota-driven market.”

The panel discussion, moderated by Susan Winkler CEO of the Reagan-Udall foundation, brought together leaders from across healthcare to examine the challenges of forecasting controlled substances, the importance of accurate data, and the broader impact on patient access.

Read our full public comments submitted during the meeting below.

Children's Hospital Association features A4C

Angels for Change was featured in the Children’s Hospital Association article, Ensuring Access to Critical Medicines for Children. The piece highlights the ongoing work to address pediatric drug shortages, including how initiatives like Project PROTECT collaborate with manufacturers to prevent disruptions and secure access to critical medicines.

The article shares how shortages of essential treatments—such as electrolytes for NICU babies—can impact care, and why building a more resilient supply chain is essential for children and families nationwide.

👉 Read the full article

2024 Annual Report

Angels for Change Releases 2024 Annual Report

Tampa, FL — Angels for Change has released its 2024 Annual Report, offering a comprehensive look at the organization’s impact over the past year in addressing drug shortages and advancing patient access across the pharmaceutical supply chain.

In a year that saw the highest number of drug shortages ever recorded—323 active shortages reported nationwide—Angels for Change remained committed to collaborative, systems-based solutions. The report outlines measurable progress across advocacy, policy engagement, emergency response, and supply chain resilience.

Key highlights include:

• Over 750,000 treatments accessed through our Drug Shortage Hotline and Global Supply Sharing Network

• A 98% success rate in addressing patient needs during active shortages

• 9 essential medicines protected through Project PROTECT

• Ongoing leadership on two federal task forces focused on drug shortages

• National growth through media coverage, strategic partnerships, and grassroots engagement

As the only nonprofit patient advocacy organization solely focused on ending drug shortages, Angels for Change continues to drive change through cross-sector collaboration, policy leadership, and patient-centered action.

Read the full report to learn more about our 2024 impact and the work ahead.